Oncologists on board for Novartis' prostate cancer radiotherapy, but logistics could hit uptake: survey

With the FDA set for a speedy review of Novartis’ new targeted radioligand therapy for a stubborn form of prostate cancer, a new survey by Cardinal Health shows the drug is already winning favor with oncologists.

But although the majority of cancer specialists are showing enthusiasm for the therapy, known as 177Lu-PSMA-617, they also pointed to logistical challenges that could dampen its uptake.